HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Breast density’s effects on cancer risk, detection a ‘fast-moving target’ in research
-
- Is automated whole-breast ultrasound a valid supplemental screening modality for all women with dense breasts?
- John McCain, Frank Underwood and Salman Rushdie: Beyond The Hunger Games Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- TAILORx ‘shows path’ to de-escalate therapy for some women, raises treatment questions for others Douglas Yee, MD
- Pediatricians’ knowledge of HPV-related diseases, limited immunization of boys hinders uptake Kenneth A. Alexander, MD, PhD
- APPs should encourage utilization of tumor treating fields for glioblastoma David L. Jennings II, MSN, RN, AGPCNP-BC
- Neoadjuvant PARP inhibitor yields ‘profound results’ in BRCA-positive breast cancer
- Study results call into question upper age limit for cervical cancer screening
- Surgeons require additional palliative care education
-
- Men less likely than women to accept palliative care
- Fratricide-resistant CAR T-cell therapy may have utility in acute lymphoblastic leukemia
- UCLA researchers receive grant to study combination therapy for lung cancer
- PD-1 blockade provides ‘dramatic advance’ for the treatment of advanced melanoma
- Cancer treatment costs cause financial toxicity, warrant discussion
- Durvalumab extends OS in advanced lung cancer
- LOXO-292 safe, effective for RET-altered non-small cell lung cancer
- First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer
-
- Entrectinib safe, effective for ROS1-positive non-small cell lung cancer
- First-line atezolizumab plus chemotherapy improves PFS for lung cancer
- Opioid deaths significantly less common among individuals with cancer
- Women with lung cancer live longer than men
- Association of Community Cancer Centers announces award recipients
- ‘Simply not acceptable’ to ignore financial toxicity of cancer treatment
- Adjuvant radiotherapy confers modest survival benefit for ductal carcinoma in situ
- Deadly subtype makes up 17% of metastatic prostate cancers
-
- Ultrasound-guided doxorubicin increases chemotherapy concentration for liver tumors
- Evaluation of postmenopausal bleeding can lead to early detection of endometrial cancer
- Pediatric CAR T-cell therapy guidelines highlight need for interdisciplinary monitoring
- Persistent mutations in bone marrow associated with poor myelodysplastic syndrome outcomes
- Frailty index predicts outcomes for older patients with myeloma
- Guidelines highlight ‘best practices’ for liquid biopsy during treatment of non-small cell lung cancer
- CDC: Oropharyngeal squamous cell carcinoma now most common HPV-associated cancer
- Risk for cancer-associated thrombosis high with implanted ports
-
- Intravesical gemcitabine after surgery significantly reduces bladder cancer recurrence
- Researchers identify non-BRCA genes associated with breast, ovarian cancers
- Chemotherapy after involved-field radiotherapy improves PFS for follicular lymphoma
- HPV-related oropharyngeal cancer incidence increasing among older adults
- FDA grants orphan drug designation to OBI-3424 for acute lymphoblastic leukemia
- FDA grants Keytruda priority review for Merkel cell carcinoma
- FDA lifts partial clinical hold on tazemetostat trials
- Cancer immunotherapy pioneers win Nobel Prize
-
- UK panel rejects Kymriah for adults with lymphoma due to cost
- University Hospitals Cleveland Medical Center appoints surgical oncology chief
- Rutgers Cancer Institute of New Jersey names breast surgery chief
- NewYork-Presbyterian/Weill Cornell Medical Center names breast surgery chief
- Avelumab plus axitinib improves PFS in advanced renal cell carcinoma